

4 APRIL 2024

HITIQ Granted New Australian Patent

- > **HITIQ has been awarded a fourth Australian Patent covering IP related to its Nexus™ technology.**
- > **The Patent increases protection of HITIQ's commercial Intellectual Property (IP) position as a leading provider of concussion management technologies.**

HITIQ Limited (ASX: HIQ) (HITIQ or the Company), a global leader in concussion management technologies, is pleased to announce the Company has been awarded an Australian Patent, further strengthening its IP portfolio related to its Nexus™ instrumented mouthguard head impact technology.

The Patent (No. 2020219864) *"Instrumented mouthguard devices and components configured for use in instrumented mouthguard devices,"* covers the embodiment of hardware components including accelerometer modules which enable monitoring of head movements of a mouthguard wearer.

The Company considers the Patent to be a valuable IP asset that enables sophisticated design and manufacturing methodologies of embedding a flexible circuit board onto a mouthguard body, allowing for enhanced device function, comfort, and data quality.

HITIQ has now secured four patents in Australia that are designed to comprehensively protect the Company's commercial IP position as a leading provider of concussion management technologies:

- Australian Innovation Patent (Patent No. 2021107528) issued 7 Feb 2022 - ***"Technology Adapted To Facilitate User-Specific Calibration Of Instrumented Mouthguard Devices, Including Calibration Methods For Instrumented Mouthguard Devices"***;
- Australian Innovation Patent (Patent No. 2021107530) issued 23 February 2022 - ***"A Protective Mouthguard Device Configured To Enable Measurement Of Circulatory System Parameters"***;
- Australian Innovation Patent (Patent No. 2021107529) issued 18 August 2022 - ***"Technology Adapted for Improved Assessment of Cognitive Function in A Human Subject, Including Assessment of Cognitive Function Affected By Brain Injuries Sustained During Sporting Activities"***; and
- Australian Patent (Patent No. 2020219864) issued 4 April 2024 - ***"Instrumented mouthguard devices and components configured for use in instrumented mouthguard devices."***



HITIQ's Nexus™ instrumented mouthguard technology is embedded in a custom fit, custom calibrated mouthguard, and through independently validated impact sensors, captures the frequency, location and intensity of all head impact exposures. For further information visit: www.hitiq.com/nexus

Commenting on the Patent, HITIQ Chief Executive, Mike Vegar, said:

“Protecting our IP is an ongoing focus as a part of our commercial strategy that will continue to secure our position as the global leader in concussion management technologies.

We have a pipeline of global patent initiatives across our suite of products which the Company will develop and activate as required.”

This announcement is authorised for release by the HITIQ Board of Directors.

- Ends -

For more information, contact: investors@hitiq.com

About HITIQ

HITIQ has an evidenced-based brain care solution company deploying world-class technologies.

Our solutions include a sensor-enabled mouthguard to an AI-enabled data analytics interface and, best in class return to play/work support software.

Our technology enables data driven decisions for thousands of professional and amateur sports players who experience brain impacts, empowers clinicians who care for their brains and enhance concussion management policies for progressive leagues around the globe.

Our customers include the Australian Football League (AFL), English Premier League (EPL), and the National Rugby League (NRL), along with numerous other teams in a variety of sporting codes. We also service universities and research organisations studying the impacts (both short and long-term) of repeat head impacts.